Siemens and Exyte join forces to fast-track construction of smart biotech facilities

COVID 19 poses major challenges for developing and mass-producing vaccines and medicines in existing production facilities. Siemens and Exyte combine their strengths to offer intelligent, modular, and scalable biotech facilities
Siemens and Exyte join forces to fast-track construction of smart biotech facilities
Nuremberg (Germany) 

Siemens, which provides solutions for process automation and digitalization, and Exyte, a global leader in the design and delivery of biopharmaceutical manufacturing facilities, have joined hands to offer end-to-end solutions for the biopharmaceutical industry by combining the digitalisation expertise of Siemens with the innovation boost from Exyte.

Against the background of the current challenges associated with the COVID 19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they offer standardized, turnkey solutions compliant with cGMP (current Good Manufacturing Practice) and GAMP (Good Automated Manufacturing Practice) to biotechnology manufacturers as well as cell and gene therapy manufacturers.

Eckard Eberle, CEO Siemens Process Automation, said, “We are excited to collaborate with Exyte to provide pre-fabricated, modular biotechnology solutions with our technology already embedded. As a market leader for the pharmaceutical industry, we offer know-how for process automation with our Simatic PCS 7 and WinCC automation platforms, as well as power supply and fire protection for modular cleanrooms.”

Currently, the first buildings with Siemens’ technology and ExyCell modules are being designed for cell and gene therapy manufacturing and biologicals production in China and Europe.

Luca Mussati, Vice President Pharmaceuticals & Biotechnology at Exyte, stated, “Our partnership with Siemens enables us to pre-integrate Siemens’ technology into ExyCell modules, thus offering clients end-to-end solutions for their facilities. Our collaboration allows our clients to reap the benefits of industry 4.0 without the necessity of engineering them from scratch each time, thus saving them time and money. ExyCell modules are suitable for new buildings as well as for the retrofit of existing buildings, and can be provided either in standard, off-the-shelf plant configurations, or modules that can be combined to meet specific customer requirements.”

Exyte is a global leader in the design, engineering, and delivery of facilities for high-tech industries. With a history of more than 100 years, the company has developed a unique expertise in controlled and regulated environments. Exyte has a truly global footprint, serving the most technically demanding clients in markets such as semiconductors, batteries, pharmaceuticals, biotechnology, and data centers. The company offers a full range of services from consulting to the managing of turnkey solutions – delivered to the highest quality and safety standards. Solving the most complex challenges, Exyte forges trusted, long-lasting relationships with its clients. In 2018, Exyte generated sales of Euro 3.5 billion with over 5,600 highly experienced and motivated employees. The company is ideally positioned to further strengthen its market leadership with its broad industry insight and its exceptional talents.

Share post:

Related Stories